Treatment of Recurrent Hepatitis C After Liver Transplantation
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
In France, 50% of the hepatitis C virus carriers develop chronic clinical hepatitis, which
may lead to cirrhosis and liver transplantation. Transplant infection by hepatitis C virus is
constant after transplantation. This recurrence usually causes chronic liver disease, in 50
to 80% of the patients. The interest of a long-term treatment with ribavirin alone after
transplantation has not been clearly demonstrated. The objective of our study is to evaluate
the efficacy of ribavirin as a maintenance treatment after a one year interferon-α /
ribavirin therapy on hepatitis C recurrence in the transplanted liver.
Phase:
Phase 3
Details
Lead Sponsor:
Rennes University Hospital
Collaborators:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Ministry of Health, France